Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setmelanotide in early-onset obesity due to POMC or PCSK1 deficiency
2016-002320-83Phase 3Completed
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Jun 2016
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of setmelanotide in pro-opiomelanocortin deficiency and PCSK1 deficiency (PCSK1D) (3 arms), sponsored by Rhythm Pharmaceuticals. Primary endpoint: Proportion of patients with at least 10% weight loss at approximately 1 year. Started Jun 2016; status: completed.
02
Drugs
setmelanotide
03
Conditions
pro-opiomelanocortin deficiencyPCSK1 deficiency (PCSK1D)
Beyond the preview
Go deeper on 2016-002320-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002320-83.